



MANCHESTER
1824

The University of Manchester

Manchester Academic Health Science Centre (MAHSC)

Partnership for the Patient - Bringing Benefit through Research,
Education and Innovation

Directory 2010

MAHSC is a partnership between The University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester Mental Health and Social Care Trust, NHS Salford (Salford Primary Care Trust), Salford Royal NHS Foundation Trust, The Christie NHS Foundation Trust, University Hospital of South Manchester NHS Foundation Trust



Contents

1 MAHSC Partners

- 2 The University of Manchester
- 2 Central Manchester University Hospitals NHS Foundation Trust
- 3 Manchester Mental Health and Social Care NHS Trust
- 4 Salford Royal NHS Foundation Trust
- 4 NHS Salford (Salford Primary Care Trust)
- 5 The Christie NHS Foundation Trust
- 6 University Hospital of South Manchester NHS Foundation Trust

7 MAHSC partner assets and linked organisations

- 8 Manchester Biomedical Research Centre (BRC)
- 8 Centre for Integrative Mammalian Biology (CIMB)
- 9 The CLAHRC for Greater Manchester
- 10 Greater Manchester Comprehensive Local Research Network (GMCLRN)
- 10 Manchester Cancer Research Centre (MCRC)
- 11 Manchester Interdisciplinary Biocentre (MIB)
- 12 Manchester: Integrating Medicine and Innovative Technology (MIMIT)
- 12 Northwest e-Health (NWeH)
- 13 TrusTECH
- 14 University of Manchester Business Relations Team (BRT)
- 14 University of Manchester Incubator Company (UMIC)
- 15 University of Manchester Intellectual Property Company (UMIP)
- 16 Wellcome Trust Centre for Cell Matrix Research (WTCCMR)
- 16 Wellcome Trust Clinical Research Facility (WTCRF)
- 17 Wolfson Molecular Imaging Centre (WMIC)

This Directory is specifically aimed at providing further information about organisations, programmes and projects within and directly linked to MAHSC to industry and other stakeholders. MAHSC is keen to work with external partners to achieve our vision. Goal Five of our Strategy is to “partner more widely and more beneficially with the commercial sector” while Goal Six is to “contribute significantly to innovation, enterprise and economic development in the city region and wider North West of England”.

If you cannot find the information you require in this directory please contact:

Dr Linda Magee
Chief Operating Officer
MAHSC
Simon Building, Brunswick Street
Manchester M13 9PL

tel + 44 (0)161 306 0639
email mahsc@manchester.ac.uk
www.mahsc.ac.uk

MAHSC Partners

The University of Manchester

The University of Manchester is the UK's largest single-site university with more than 35,400 undergraduate and postgraduate students and 5,800 academic and research staff. The University has an annual income of more than £680 million and had a total research expenditure of £375 million in 2006-07.

According to the results of the 2008 Research Assessment Exercise, The University of Manchester is now one of the country's major research institutions, rated third in the UK in terms of 'research power' behind only Oxford and Cambridge. The University attracts world-renowned researchers and teachers and boasts no fewer than 23 Nobel Prize winners among its current and former staff and students.

Our tradition of success stretches back 180 years. The birth of the modern computer, the splitting of the atom, the founding principles of modern economics and many more world-changing innovations have their roots at The University of Manchester. Today, we enjoy a global reputation for our pioneering, problem-based approach to learning, alongside our internationally renowned research, which is no doubt one of the reasons why we attract more applications from potential students than any other UK university.

Since 2005, The University of Manchester has risen year on year in the influential Academic Ranking of World Universities Survey conducted by Shanghai Jiao-Tong University. In 2008, we ranked 6th in Europe and 40th globally, confirming the University as a world-class teaching and research institution. Our mission is to become one of the top 25 universities in the world by 2015 and the preferred destination for the best students, teachers and researchers. It's a goal that we are well on the way to achieving, backed by a major investment programme in facilities, staff and buildings.

The University has 22 academic schools and hundreds of specialist research groups undertaking pioneering multi-disciplinary teaching and research of worldwide significance. We are at the forefront of finding solutions to some of the world's most pressing problems, boasting strong collaborative links with industry and the public services. We are one of the world's top universities for biomedical research, leading the search for new treatments for life-threatening diseases.

Contact

Aeron Haworth
Media Relations, Medical and Human Sciences
The University of Manchester, Oxford Road
Manchester M13 9PL

tel +44 (0)161 275 8383
mobile +44 (0)7717 881563
email aeron.haworth@manchester.ac.uk
www.manchester.ac.uk

Central Manchester University Hospitals NHS Foundation Trust (CMFT)

The Trust comprises the following hospitals: Manchester Royal Infirmary; Saint Mary's Hospital; Manchester Royal Eye Hospital; Royal Manchester Children's Hospital and the University Dental Hospital. It has undergone a major programme of building and development resulting in major new hospitals complex.

The new Manchester Royal Eye Hospital opened to patients on 8th August 2009. It is one of the largest eye teaching hospitals in Europe and globally acknowledged as a centre for excellence. It provides care to residents of Greater Manchester and beyond.

The new Manchester Royal Infirmary wing is complete and opened to patients on 11th July 2009. Many of the medical services which are currently housed in the older parts of the Manchester Royal Infirmary have relocated into the purpose-built facilities in the new build. These services include haematology, renal and acute medicine. The new haematology unit comprises of in-patient/out-patient and day case facilities. The in-patient ward has 14 state-of-the-art isolation cubicles for patients undergoing bone marrow transplantation. In total there are 22 in-patient beds. The renal dialysis unit moved into the new build in 2007 and the renal wards are now co-located within this area.

The new Saint Mary's Hospital opened to patients on 13th July 2009 and is one of the centres of excellence for in-patient services for maternity. In the new facility there are 8 en-suite delivery rooms, together with a purpose-built Midwife-led unit. The facility also includes a newborn intensive care unit along with genetics, gynaecology, the sexual assault referral centre and radiology.

The new Royal Manchester Children's Hospital opened to patients on 11th June 2009. It brings together the specialist services previously provided at the Booth Hall and Pendlebury Children's Hospitals. The new children's hospital includes the paediatric intensive care unit which is one of the leading centres in the North West and a paediatric emergency department.

Contact

Dr Penny Johnson
BRC Industry Liaison Manager
Central Manchester University Hospitals
NHS Foundation Trust
Manchester Royal Infirmary
Off Grafton Street, Manchester M13 9WL
tel +44 (0)161 901 2679
mobile +44 (0) 7827 969 105
email penny.johnson@cmft.nhs.uk
www.cmft.nhs.uk

Manchester Mental Health and Social Care NHS Trust (MHSC)

Manchester Mental Health and Social Care Trust's Research and Development Department have an international reputation for their groundbreaking work in areas such as suicide prevention, the development of innovative services and research into looking after people with dementia.

The department was recently named second in the country in attracting National Institute for Health Research funding in Department of Health league tables, only being kept off the top spot by South London & Maudsley NHS Foundation Trust. The team has ambitions to become the National Centre of Excellence for Mental Health Research and regard membership of MAHSC as a key part of this process.

The Trust is also committed to its policy of 'Research into Practice', so that work undertaken informs the actions of front-line staff. As part of this the department is determined to broaden engagement of all staff groups, and indeed service users, in carrying out research and believe that 'anyone can publish.' Research being carried out by the team is now informing national mental health policy and staff members are currently working with the National Institute for Health & Clinical Excellence (NICE) to identify methods for spreading good practice.

Contact

Lisa Dowell
Trust HQ
70 Manchester Road
Chorlton-cum-Hardy
Manchester M21 9UN

tel +44 (0)161 276 3311
email lisa.dowell@mhsc.nhs.uk
www.mhsc.nhs.uk

MAHSC Partner
logos

MANCHESTER
1824

The University of Manchester

Central Manchester University Hospitals 
NHS Foundation Trust

Manchester Mental Health 
and Social Care Trust

Salford Royal NHS Foundation Trust (SRFT)

Salford Royal NHS Foundation Trust is recognised as one of the best hospitals in the NHS and aims to provide Safe, Clean and Personal care to patients every time. Salford Royal is a large teaching hospital that provides a range of medical, surgical, maternity and emergency services to the people of Salford. The Trust also offers specialist care to people from all over the UK who require expert help with, for example, neuroscience and kidney conditions.

In October 2009, Salford Royal was named as one of the top performing hospitals in the country by the Care Quality Commission – rating the Trust ‘excellent’ for the quality of its services for the fourth year running. The Trust achieved the highest score in the NHS for patient recommendation - 98% of patients would recommend Salford Royal to their family and friends. In April 2008, Salford Royal launched one of the most ambitious plans in the NHS for quality improvement and patient safety – aiming to save an additional 1000 lives and avoid 10,000 harmful incidents to patients by 2011.

Salford Royal hosts over 350 active research projects covering five main areas: Neurosciences; Dermatology; Diabetes and Kidney Disease; Gastroenterology and Injury. In conducting and developing research the Trust works closely with The University and NHS partners and it is the only place with integrated Research and Development (R&D) directorate and governance arrangements which uses the PCT and hospital services in Salford to deliver its agreed R&D strategy. The key components of Salford’s R&D strategy are to:

- Become a premier location for community and clinical population-based research.
- Fulfill the translational research mission by ensuring that research findings are implemented in clinical and public health practice.
- Focus on existing areas of research strength: Vascular Disease (Diabetes and Renal Medicine), Inflammation (Dermatology, 3IRG and Rheumatology), Gastrointestinal Science and Neuroscience.
- Provide a “one-stop-shop” for Pharma seeking to conduct clinical trials from phase 0 (methodology development) right through to post-marketing surveillance in our areas of research strength.
- Attract, develop and retain world-class researchers.
- Maximise research income through NIHR, Research Councils and others funders

Contact

Dr Lloyd Gregory/Dr Stephen Waldeck
Associate Director, Research and Development/
Executive Medical Director
Salford Royal NHS Foundation Trust, Stott Lane, Salford
M6 8HD

tel +44(0)161 206 4734 / +44 (0)161 206 0868
email Lloyd.gregory@manchester.ac.uk /
Stephen.waldeck@srft.nhs.uk
www.srft.nhs.uk

NHS Salford (Salford Teaching Primary Care Trust)

NHS Salford, also known as Salford Teaching Primary Care Trust (PCT), is the local NHS for Salford, responsible for providing healthcare to around 230,000 people registered with Salford’s primary care services, including GPs, dentists and opticians.

NHS Salford serves a city which is well-known for its industrial heritage and links with the arts. Areas of Salford contrast between deprived and affluent and the city is a varied and multi-cultural city. Salford’s health profile is generally worse than the England average. The city is challenged by high levels of unemployment, teenage pregnancy, smoking, alcohol and drug abuse and illness generally.

NHS Salford’s recent service developments include the opening of three Gateway Centres in the city. These centres – located in Walkden, Eccles and Pendleton – are a joint venture between Salford City Council, MaST LIFTCo, Laing O’Rourke and offer a range of healthcare and local authority services under one roof.

Other service highlights include a new, specialist cervical screening service for women with disabilities and learning difficulties and the commissioning of Salford Care Homes practice, a groundbreaking GP practice which supports residents living in the city’s 51 residential and care homes.

NHS Salford has a strong interest in research and last year, along with Salford Royal NHS Foundation Trust and the University of Manchester, was awarded a £1.5million research grant by the National Institute for Health Research to help patients manage their chronic gastrointestinal orders. Working with local GPs, the purpose of the research was to find and implement ways for sufferers to cope with their gastrointestinal illnesses.

NHS Salford also leads the Manchester Collaboration for Leadership in Applied Research (CLAHRC) and was awarded £20million over five years for the programme. NHS Salford is the only PCT in the UK that has integrated research offices with secondary/tertiary care and directs the research governance function for PCTs in Greater Manchester. NHS Salford has been a national pioneer in developing an integrated e-Health link (Salford e-labs) between the acute and primary care sectors.

Contact

Jenny Aldersley
Communications Manager
NHS Salford
St James House
Pendleton Way
Salford M6 5FW

tel +44 (0)161 212 4116 (NHS Salford 0161 212 4800)
email jenny.aldersley@salford.nhs.uk
www.salford.nhs.uk

The Christie NHS Foundation Trust

The Christie is one of Europe’s leading cancer centres, treating more than 40,000 patients a year. It has a double ‘excellent’ for services and use of resources from the Care Quality Commission, and have been officially rated as the best hospital in the country for treatment and care. The Trust is an international leader in research with cancer research in Manchester officially ranked the best in the UK in December 2008 through the University Research Assessment Exercise. The Christie has a track record of world firsts for over 100 years, including the first clinical trial in the use of breast cancer drug Tamoxifen. We currently run one of the largest phase I clinical trial units in Europe.

Research is managed in partnership with the University of Manchester and Cancer Research UK – through the Manchester Cancer Research Centre – and will lead the cancer research arm of the Manchester Academic Health Science Centre (MAHSC). The Christie also offers education and training in all aspects of cancer, with plans to open a Christie School of Oncology in the future.

The Christie provides cancer services to a population of 3.2 million across Greater Manchester & Cheshire, but as a national specialist around 26% of patients are referred from other parts of the country. The Trusts hosts one of the largest radiotherapy departments in the world, chemotherapy on site and through 14 other hospitals, highly specialist surgery for complex and rare cancer and a wide range of support and diagnostic services.

The Christie is currently implementing an ambitious five-year strategy which breaks new ground and is set to transform treatment and care for cancer patients. A £72 million investment plan over the next two years includes a new £35 million patient treatment centre, which will include the largest phase I clinical trials unit in the world – and a unique £17M network of Christie radiotherapy centres in other parts of the area to deliver treatment closer to people’s homes.

Contact

Alicia Custis
Head of Communications
The Christie NHS Foundation Trust
Wilmslow Road
Manchester M20 4BX

tel +44 (0)161 446 3706
mobile + 44 (0) 7899 797065
email alicia.custis@christie.nhs.uk
www.christie.nhs.uk

MAHSC Partner
logos

Salford Royal 
NHS Foundation Trust

University Teaching Hospital

safe • clean • personal

Salford 
Primary Care Trust

The Christie 
NHS Foundation Trust

University Hospital of South Manchester NHS Foundation Trust (UHSM)

UHSM is highly active in research with themes focused on Respiratory Disease, Cancer, Cardiovascular, Wound Healing & Tissue Repair, Gastroenterology, Medicines Management and Medical Education. It has a new £14m Nightingale breast cancer centre which acts as a focus for breast cancer research in Greater Manchester and researchers within the Centre have had significant success in NIHR funding including two NIHR Programme Grants (approximately £3.2m). UHSM is also the host organisation for the NIHR Greater Manchester Local Research Network.

The long-established clinical and academic strengths in lung disease are led from the North West Lung Centre which has an international recognition. The NIHR Translational Research Facility in Respiratory Medicine is delivering a step change in translational research capability in South Manchester. Following the opening of National Aspergillosis Centre in 2009, the first such facility in the world, Aspergillosis and mycology will contribute to major themes of the NIHR Translational Research Facility. UHSM is a major centre for cardiology, cardiothoracic surgery and cardiopulmonary transplantation, stroke, venous disease, thrombosis and coagulation. The opening of the £22m North West Heart Centre at Wythenshawe Hospital in 2008 further strengthened cardiac research and clinical care, including world class imaging. Our major burns and plastic/reconstructive surgery centre forms an inter-disciplinary centre of excellence for research in tissue injury and repair at the leading edge of translational research to develop new therapies. Wythenshawe Hospital is the main NHS site for clinical trials of innovations arising from the University laboratories, taking excellent basic science through to clinical applications for the benefit of patients. The Gastrointestinal unit concentrates on research into the clinical, epidemiological and pathophysiological aspects of the functional gastrointestinal disorders. It has an international reputation for developing better treatments and exploring new therapeutic options such as recent studies on probiotics, food antibodies and hypnosis.

The UHSM Education Academy

UHSM, led by Director Ged Byrne, aspires to be the future leader for healthcare education. In order to deliver this aim, UHSM has created a healthcare 'academy' which takes overall responsibility for the delivery of educational activity within the Trust. The academy, under the direction of a steering group of expert multi-professional educators, is developing and delivering an entirely new governance system for education, specifically promoting:

- inter-professional learning to improve patient safety
- simulated learning including a new state-of-the-art simulation centre, a mobile clinical skills bus, and a faculty specialising in simulated education.
- multi-professional e-learning facilities.
- a new relationship with our local community which will deliver novel learning opportunities based on the whole patient journey.
- a structured programme of learning in the global community and delivering sustainable healthcare in sub-Saharan developing economies.

Contact

Professor Jonathan Cooke
Director of Research and Development and Clinical Director of Pharmacy and Medicines Management
University Hospital of South Manchester
NHS Foundation Trust
Wythenshawe Hospital
Manchester
M23 9LT

tel + 44 (0) 161 291 4195
fax + 44 (0) 161 291 2285
email jonathan.cooke@uhsm.nhs.uk
www.uhsm.nhs.uk

University Hospital of South Manchester 
NHS Foundation Trust



MAHSC Partner Assets and Linked Organisations

NIHR Manchester Biomedical Research Centre

Putting research at the heart of healthcare

The National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC) is a partnership between the Central Manchester University Hospitals NHS Foundation Trust (CMFT) and The University of Manchester. The BRC is located on the Central Manchester Hospital site, within Corridor Manchester, which is the location for Europe's most comprehensive Clinical Academic Campus comprising 6 NHS hospitals and 2 universities, which over the last 10 years have been the building blocks of Manchester's research and innovation capability.

Established on 1 April 2008, the BRC is one of 12 prestige centres of medical research excellence across the UK funded by the NIHR. We are designated by the NIHR as a Centre of Excellence in Genetics and Developmental Medicine. We are particularly grateful to the North West Regional Development Agency (NWRDA) for funding support which has enabled us rapidly to accelerate our research programmes with recruitment of new Professional level Clinician Scientists and establishment of high quality technology capabilities including a Tissue Biobank and a state of the art genomics, proteomics and metabolomics facility to push forward the translation of research ideas into new therapeutics, diagnostics and devices.

The BRC brings together the skills of clinician-scientists, scientists, doctors, nurses, midwives and allied health professionals based across Europe's largest single site clinical academic campus. Manchester already has a well-established research infrastructure, and the BRC will invest more than £50 million during the next four years in new staff, facilities and equipment.

Our aim is to translate developments in biomedical research, moving research ideas from the laboratory through clinical trials into the Trust's five hospitals, where they can benefit patients from Greater Manchester and beyond. BRC researchers and clinicians are tackling some of the highest priority disease areas affecting the local population. From trials of a new drug treatment for the most common cause of blindness in older people, to developing a blood test to identify pregnant women at risk of complications, our emphasis is on using science to help deliver better health.

We work closely with companies and our partner organisations in the biotech and pharma sector to achieve this, and we are actively seeking new partnerships and collaborations with pharmaceutical, biotechnology, and healthcare companies.

The Manchester BRC is supported by the NWRDA, which is delivering key economic development opportunities through its investment in biomedical research. You can contact us to arrange a visit or discuss your collaborative needs as follows:

Contact

Dr Penny Johnson
BRC Industry Liaison Manager

Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary, Off Grafton Street Manchester M13 9WL

tel +44(0)161 901 2679 mobile +44(0)7827 969 105
email penny.johnson@cmft.nhs www.cmft.nhs.uk/brc

The Centre for Integrative Mammalian Biology

The Centre for Integrative Mammalian Biology is an academic consortium formed by the Universities of Manchester and Liverpool, as part of an initiative to build capacity in integrative mammalian biology (IMB). The consortium is funded by an award from research councils, pharmaceutical companies and the Northwest Development Agency.

The centre aims to deliver education, training and alliances in in vivo research to the highest scientific and ethical standards. As well as around 700 IMB researchers we have a dedicated Experimental Officer and Business Development Manager to ensure that the interface between academia and industry maximises the possible synergies with our huge range of activities. This can take the form of training in in vivo techniques (both practical and theoretical) or research (traditional collaborative, fee for service or the use of our facilities to complement your own infrastructure) all leading to bespoke in vivo opportunities that we believe is unrivalled anywhere in the UK.

The value to industrial partners is several fold. Firstly, fostering more contacts with academic key opinion leaders, adding value to internal research programmes with the option to raise external profile by publication of pre-competitive work. Secondly the size and scope of the centre's research interests is extensive with leading expertise in numerous therapeutic areas (oncology, CNS disorders, pain, inflammation, injury and repair, metabolic disorders, gastrointestinal disease, reproductive physiology and veterinary science) across a wide range of species. Finally we offer access to world leading groups working on key areas in drug safety and toxicology. This puts us in the privileged position of being able to utilise our wide and varied in vivo resource to impact companies' portfolios from early target identification and validation through efficacy testing to identification of toxicology and safety issues for candidate molecules and classes.

Contact

Dr Fraser Murray
Business Development Manager
Centre for Integrative Mammalian Biology
The University of Manchester, Oxford Road
Manchester M13 9PL

tel +44(0)161 275 5063
email fraser.murray@manchester.ac.uk
www.manchester.ac.uk/centreforIMB

The CLAHRC for Greater Manchester

The CLAHRC for Greater Manchester carries out high quality applied health research in the NHS and implements it to benefit patients across Greater Manchester. The CLAHRC is one of nine funded across England and has the specific role of translating research into practice, by developing new interventions, which will be effective and appropriate for everyday use in the NHS and implementing and evaluating these interventions in routine clinical practice. Working with commissioners and frontline staff, interventions will then also be applied into different settings across the health economy.

The CLAHRC is collaboration between NHS primary care, acute trusts, mental health trusts and the University of Manchester. The CLAHRC is funded for five years and started in October 2008. Funding for the initiative was given by the NIHR (£10 million) and the Greater Manchester Primary Care Trusts (£10 million).

Key objectives:

- To support patient self-management and improve quality of care for people with vascular disease by developing and evaluating a series of inter-related interventions.
- To improve health care provision and reduce inequalities in access to care by implementing these and other evidence-based interventions in the NHS across Greater Manchester
- To build NHS capacity to plan and implement evidence-based changes to care pathways for people with vascular disease through close working and knowledge transfer between University staff and NHS providers and commissioners

Research: Established research teams are developing high quality outputs. Each theme forms one component of an integrated plan to improve NHS support for patient self-management and reduce inequalities in access to care. Interventions will be developed and tested through randomised controlled trials and focus on disadvantaged groups.

- Patients with Long Term Conditions: new information resources to support patient self-management.
- Health Care Practitioners: new approaches to managing patients with depression who are also suffering from heart disease and diabetes.
- Health Care Services: new models of access to specialist care to support patients with chronic kidney disease and diabetes.
- Health Information Systems: working with all the research themes to develop the use of information resources to analyse and plan care pathways for patients with vascular disease. Models will be developed by software experts to map implications for health care provision.

Implementation: The first phase of work (2008-2010) will focus on rolling out existing evidence-based activities.

- Stroke: raising awareness of stroke signs and symptoms with frontline practitioners and the public; developing a six month post stroke review.
- Diabetes: developing a telephone contact system for patients with diabetes and other long term conditions.
- Chronic Kidney Disease: increasing ascertainment rates and improving the quality of management of patients with CKD in primary care.
- Heart Disease: mapping the current discharge process for heart failure and patients with arterial fibrillation.

Contact:

Professor Bonnie Sibbald, Director
(or **Dr Julia Miller, Chief Operating Officer/Professor Ruth Boaden, Deputy Director**)
Collaboration for Leadership in Applied Health Research & Care
Suite 204, Innovation Forum
Frederick Road, Salford M6 6FP

tel +44(0)7545422404
email clahrc@srft.nhs.uk
www.clahrc-gm.nihr.ac.uk

MAHSC Partner Assets
and Linked Organisations logos



Collaboration for Leadership in
Applied Health Research and Care

Greater Manchester Comprehensive Local Research (GMCLRN) - Commercial Liaison

Greater Manchester CLRN is building a world class NHS infrastructure for clinical research across all 24 NHS organisations and ten boroughs of Greater Manchester.

GMCLRN has prioritised seven research areas for major investment: Cancer, Vascular, Respiratory, Mental health, Inflammation and Repair, Human Development and Primary care. These areas represent the greatest health burden for the conurbation and correspond with the majority of clinical research activity.

The GMCLRN industry team communicates proactively with the Priority Groups and their investigators to identify which therapeutic areas and companies are most appropriate for them to work with.

GMCLRN organises regular meetings between pharmaceutical companies and members of the Priority Groups to provide links with specific industry research personnel and to discuss company pipeline and horizon plans plus their own research areas. These meetings are organised by the Industry team who match the Priority Group teams to the companies via a proactive mapping process. The Industry team produces regular activity summaries for each therapy area to assist companies and researchers with improving their performance. Such active processes afford cooperation at an early stage of compound and protocol development so that investigators and resources are in place to deliver studies to time and target.

NW Exemplar Programme

The NHS in the North West is currently taking part in an Exemplar Programme that is bringing together all aspects of the NIHR CRN with partners in the pharmaceutical and biotechnology industries and across NHS North West to demonstrate improved commercial trial performance. It has been taken forward under the sponsorship of Industry Leaders, Department of Health and NIHR, with the support of NHS North West.

All commercially sponsored studies will be assessed but twenty studies will be closely scrutinised as the basis of the Programme. Their progress through set up and study delivery is being closely monitored and Key Performance Indicators measured. The ambition is to demonstrate comparable or better performance than leading European countries. Case study learning will be produced and disseminated as part of plans to spread best practice across the rest of the NHS and NIHR.

Contact

Paul Hedgeland, Industry Manager
Greater Manchester Comprehensive Local Research Network, Second Floor, Education & Research Centre University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road Manchester M23 9LT

tel +44(0)161 291 5887 mobile +44(0)7809560781
email Paul.hedgeland@googlegmail.com
www.ukcrn.org.uk/index/networks/comprehensive/clrn/manchester.html

Manchester Cancer Research Centre (MCRC)

Cancer research in Manchester is integrated and coordinated through the Manchester Cancer Research Centre (MCRC) which brings together the expertise, vision and resources of the partner organisations – The University of Manchester, The Christie NHS Foundation Trust and Cancer Research UK. The MCRC brings together basic, translational and clinical research and in so doing facilitates our aim to gain a better understanding of how cancer develops and apply this knowledge to the development of better treatments and diagnostics which will benefit cancer patients. The MCRC will spearhead the development of cancer research within MAHSC.

A number of new MCRC initiatives have been developed that aim to build strength in tumour specific areas such as breast and lung, in cross-cutting research areas such as early clinical trials, biomarker identification and development, radiation related research and in infrastructure such as imaging and tissue collection. One clear example of the success of this joined up approach is the MCRC Biobank, a Manchester-wide research initiative involving the five major hospital trusts in the area (The Christie, Salford Royal, Pennine Acute, Central Manchester and South Manchester) in collaboration with AstraZeneca. Tissue bank staff based in each of the participating Trusts, consent patients and organise the collection of tissue samples which are stored centrally. Over 700 samples have now been collected and around 50 patients a month are being recruited to donate samples to the Biobank.

Another example of MCRC success is the integration of early phase clinical trials and biomarker research that involves close interaction at the laboratory/clinical interface. The early phase clinical trials unit at The Christie is currently being expanded as part of the new £35M Patient Treatment Centre development and will create one of the largest dedicated units in the world. In parallel, there has been expansion in the Clinical and Experimental Pharmacology group at the Paterson Institute for Cancer Research, a group that is dedicated to identify biomarkers that predict patient response. This seamless interaction results in greater scientific depth to clinical trials.

Contact

Esther Walker
Operations Manager
Manchester Cancer Research Centre (MCRC)
The University of Manchester
Wilmslow Road
Manchester M20 4BX UK

tel +44(0)161 918 7035
email esther.walker@manchester.ac.uk
www.manchester.ac.uk/mcrc

The Manchester Interdisciplinary Biocentre (MIB)

The MIB led by Director, Professor John McCarthy, grew out of a commitment to develop a globally recognised focus of interdisciplinary research at the interface to biology at the University of Manchester. With 60 research groups, housed in a purpose-built building, the MIB provides a unique intra-structure, research environment and culture, all specifically designed to remove the barriers between disciplines and to promote innovative science.

Scientists and engineers in the MIB use advanced quantitative methods to explore the relationship between the macro behaviour of biological systems and the properties of their nanoscale components. They also see this understanding as a basis for developing new biotechnologies that will find applications in areas such as human health, the energy economy, food security, industrial transformations and the environment. A defining feature of the MIB's mission is the incorporation of rigorous, cutting-edge principles and technologies derived from the physical sciences, engineering, mathematics and computation into novel approaches to elucidating the molecular mechanisms that underpin living processes and systems. An extensive programme of technology development lies at the heart of our research programme, driven by expertise from the quantitative sciences and engineering, allowing us to accelerate progress through the implementation of state-of-the-art enabling technologies.

The research focuses around three fully complementary and synergistic research themes coupled to an extensive programme of technology development:

- Biomolecular Mechanism and Catalysis examines the properties and mechanistic details of biomolecular and biotechnological processes ranging from complex multi-component pathways and complexes to single proteins (enzymes).
- Systems Biology uses information obtained through experimental analysis and models this in the complex environment of the living cell.
- Molecular Bioengineering encapsulates research whose primary focus is the design, creation and application of biomolecular systems utilising natural or modified biological components and/or non-biological components in novel combinations.

Contact

Dr Rosalind Le Feuvre
MIB Research and Planning Manager
Manchester Interdisciplinary Biocentre,
The University of Manchester,
131 Princess Street, Manchester. M1 7DN

tel +44(0)161 3065184
email r.a.le-feuvre@manchester.ac.uk
www.mib.ac.uk

MAHSC Partner Assets
and Linked Organisations Logos



MIMIT – Manchester: Integrating Medicine and Innovative Technology

MIMIT – Manchester: Integrating Medicine and Innovative Technology, is the first international affiliate of CIMIT® a collaborative initiative of world renowned academic and healthcare delivery organisations in Boston, US. The primary aim of MIMIT is to improve patient care by bringing scientists, engineers and clinicians together to catalyze development of innovative healthcare technologies through scoping and validation of unmet clinical need.

MIMIT™ comprises a community of senior representatives throughout Manchester Academic Health Science Centre* partner organizations, to identify both clinical need and innovation exploitation potential. These 'Site Miners' are the catalyst for forming partnerships to address clinical problems that require an engineering solution. MIMIT also facilitates academics and clinicians in working with their intellectual property office (ie UMIP and TrusTECH) and provides pump-priming project investment.

The MIMIT Industry Liaison Programme is designed to provide the most efficient route to forming collaborative relationships to design and develop innovative technology. Our approach supports a targeted scoping programme commissioned by industry or the creation of dedicated project teams to address pre validated clinical unmet needs.

The strength of MIMIT is its provision of pump priming investment, ability to tap into a comprehensive clinical network to validate unmet clinical needs, project manage at every stage of the innovation cycle and facilitate in the realization of longer term investment.

Contact

Dr Roz Kelly
Head of Operations
Manchester: Integrating Medicine and Innovative Technology (MIMIT)
Area 1.035 Manchester Interdisciplinary Biocentre
University of Manchester
Princess Street
Manchester M1 7DN

tel +44(0)161 3065121
email Rosalind.kelly@manchester.ac.uk
www.mimit.org.uk

Northwest e-Health (NWeH)

Northwest e-Health (NWeH) is a collaboration between Salford Royal NHS Foundation Trust, Salford Primary Care Trust and the University of Manchester.

NWeH produces software tools to transform health record data into: better-informed care for patients and communities; and better-prepared environments for healthcare innovation.

Our e-Lab technology enables healthcare organisations, such as Primary Care and Acute Trusts, to assemble patient information, analytical methods and expertise quickly - providing business intelligence & reporting, clinical calculations, public health intelligence and research tools. The e-Lab protects the privacy of patients while providing auditable, low-cost, high-quality, reproducible analyses - building local capacity for making sense of local healthcare.

Contact

Dr Burrinder Grewal
Chief Executive Officer
Jean McFarlane Building
University of Manchester
Oxford Road
Manchester M13 9PL

tel +44(0)161 306 7387
email burrinder.grewal@nweh.org.uk
www.nweh.org.uk

TrusTECH

TrusTECH is hosted at the Central Manchester University Hospitals NHS Foundation Trust. It is one of a national network of NHS Innovation Hubs and currently works with around 60 NHS organisations across the North West to provide a competent and effective innovation management service. Working with individual NHS Trusts, it responds to requests to evaluate new technology and service innovations and provides advice on how these can be protected, developed and exploited for the benefit of the NHS. It discovers new technological solutions to NHS problems and captures new service delivery innovations that are made available widely across the NHS regionally and nationally.

TrusTECH works with NHS staff across all disciplines and has experience in managing a diverse range of innovations, including those in the following fields:

- Diagnostics and therapeutics
- Medical devices and equipment
- Software and training/educational materials
- Service delivery

TrusTECH in addition works with private sector organisations to assist them to access the NHS to undertake clinical trials and evaluations to provide high quality clinical evidence of the effectiveness of new products, equipments and diagnostics.

During the last 8 years of operation TrusTECH has:

- Provided support to NHS organisations through regular training programmes to help staff to understand the benefits that properly managed innovation can bring to the NHS, and has participated in over 250 events, reaching over 12,000 NHS staff.
- Ran regional innovation award schemes to promote and showcase the benefits of actively managed innovation, supporting staff and organisations to develop their innovations.
- Brought numerous innovative products and services through from concept to clinical use/implementation
- Initiated, developed, managed or contributed, many new innovative programmes eg ACTNoW (Advancing Clinical Trials Across the Northern Way), MedilinkNW, National Technology Adoption Centre (NTAC), Smart Solutions for Health Care Associated Infections and Manchester Integrating Innovative Medical Technologies (MIMIT)

Contact

Dr Richard Deed
Innovation Unit Manager
1st Floor, The Postgraduate Centre
Manchester Royal Infirmary, Oxford Road
Manchester, M13 9WL

tel +44(0)161 276 5764
email innovations@trustech.org.uk
www.trustech.org.uk

MAHSC Partner Assets
and Linked Organisations logos



The University of Manchester Business Relations Team (BRT)

First rank international universities are characterised by strong collaborative relationships with major companies, and by being major sources of invention, intellectual property, and spin-out activity. Such activities have a strong positive effect on the vitality and innovation within the overall research portfolio of these universities.

As one of the UK's top-ranked universities, with a rich heritage and an exciting agenda for the future, The University of Manchester sees this approach as central to its mission.

The University of Manchester Business Relations Team (BRT) provides strategic business relations support to the University's senior management in achieving the following goals:

- The creation of collaborations, partnerships and alliances with key businesses that result in a significant mutual benefit to both partners.
- The development of world-leading programmes in research and education leading to substantive economic, societal and cultural impact.
- To aid in the ongoing development of the City of Manchester and surrounding region as a major node of the UK knowledge economy.

The BRT manages the University's key strategic collaborative relationships with industry across all major sectors, and acts as a hub at the academic-industry interface to enable industry partners to clearly view possible collaborative alignments with the University's research strengths. It also plays a key role in finding collaborative solutions to solve industry research, development and training needs, often by building diverse interdisciplinary collaborations across one of Europe's broadest-based research universities.

Staffed by an experienced team of Business Development Managers, many with a combined background in academic research and commercial business, the BRT provides an insight into how industry can best realise 'return on investment' from a collaborative relationship.

Contact

Dr Mike Musialowski
Lead Business Development Manager for Healthcare and Biosciences
Business Relations Team, The University of Manchester,
Simon Building, Brunswick Street, Manchester,
M13 9PL

tel +44(0)161 275 7985 / 306 9106
email mike.musialowski@manchester.ac.uk
www.manchester.ac.uk

The University of Manchester Incubator Company Limited (UMIC)

The University of Manchester Incubator Company Limited (UMIC) is The University's Incubator facilities management and external business mentoring commercialisation company.

UMIC manages current and future Incubators for The University including the successful Manchester Bioscience Incubator, Core Technology Facility, North Campus Incubator, One Central Park Incubator and Broadstone Mill. UMIC also provides business mentoring services to regional SMEs across all business sectors and is part of the very successful northwest regional biomedical cluster, Bionow.

UMIC is currently working on the development of the next generation of start-ups to follow the successes of Renovo, DxS, Epistem and Gentrionix in particular. This year, UMIC celebrated ten years of successful Biotechnology Business Incubation. Over 30 companies have been through the Incubator and Core Technology Facilities, with over 800 jobs created, and greater than £200M in sales generated and venture capital invested. In addition, UMIC now has an overall portfolio of greater than 60 SMEs across its incubators and all market sectors with an active alumni programme.

Contact

Dr Martino Picardo
Managing Director
UMIC Ltd
Incubator Building
48 Grafton Street
Manchester M13 9XX

tel +44(0)161 603 7655
email martino.picardo@umic.co.uk
www.umic.co.uk

The University of Manchester Intellectual Property Limited (UMIP)

The University of Manchester Intellectual Property Limited (UMIP) is the managing agent of The University of Manchester for intellectual property commercialisation. UMIP's role is to enhance the scale and quality of The University's intellectual property development and commercialisation activities. UMIP works in highly positive relationships with researchers, entrepreneurs, business people, professional advisers and investors to achieve its goals. As a successful company it employs modern management approaches to licensing, joint ventures and spin-out enterprises. UMIP has a flexible and tailored approach to each commercial opportunity to ensure that the possibilities and benefits for intellectual property transfer to the market-place are maximised.

The University of Manchester is particularly strong in biomedical research and has an impressive track record of biotechnological innovation and development toward products and services that address patient needs. Current and past commercialisation projects include a new anaesthetic device, training skills for risk management in mental health, osteoarthritis assessment tool and e-learning package for infection control.

Based in the heart of the growing northwest biotechnology cluster, UMIP's Biomedica Team is responsible for identifying, protecting and commercialising the University's biomedical intellectual property. The team comprises eight professionals who manage biotechnology business development projects on behalf of the University often in collaboration with partner Healthcare Trusts. Biomedica team act as an interface with biotechnology companies and investors to license biotechnology, create and fund spin-out companies and secure mutually beneficial industrial collaborations.

Contact

Eileen Priestner, PA to Dr Rich Ferrie, Head of Biomedica Group
The University of Manchester Intellectual Property Ltd (UMIP)
The Incubator Building
48 Grafton Street
Manchester
M13 9XX

tel +44(0)161 606 7200
email bio@umip.com
www.umip.com

MAHSC Partner Assets
and Linked Organisations logos



The University of Manchester



The University of Manchester
UMIC



The University of Manchester
UMIP

The Wellcome Trust Centre for Cell-Matrix Research

The Wellcome Trust Centre for Cell-Matrix Research (WTCCMR) is a multidisciplinary research centre embedded within the Faculty of Life Sciences at the University of Manchester. The long-term aims of the WTCCMR are to elucidate the structure and function of extracellular matrices (ECM) and their cellular receptors, to define the role of ECM and cell-ECM interactions in normal development and human diseases, and to develop approaches for preventing and treating such diseases.

The Centre comprises 23 principal investigators, drawn from both the Faculty of Life Sciences and the Faculty of Medical and Human Sciences, who manage independent research programmes and collaborate together under the umbrella of cell-matrix research. Current Centre members are: Clair Baldock, Christoph Ballestrem, Martin Baron, Jordi Bella, Paul Bishop, Ray Boot-Handford, Keith Brennan, Mike Briggs, Ann Canfield, Tony Day, Andrew Gilmore, Tim Hardingham, Martin Humphries, Karl Kadler, Richard Kammerer, Cay Kielty, Andreas Prokop, Adrian Shuttleworth, Charles Streuli, Dave Thornton, Mark Travis, Gillian Wallis, Claudia Wellbrock

The translation of basic research discoveries for patient benefit is a key goal for the WTCCMR. The Centre has many links with clinicians in the Central Manchester University Hospitals NHS Foundation Trust and has developed a strong relationship with the Manchester Cancer Research Centre and the Healing Foundation Centre. WTCCMR members are also members of the Manchester Breast Centre, UK Centre for Tissue Engineering/Regeneration and the Northwest Embryonic Stem Cell Centre.

Contact

Anna Fildes
Wellcome Trust Centre for Cell Matrix Research
B.3016 Michael Smith Building
Faculty of Life Sciences
Oxford Road
Manchester
M13 9PT

tel +44 (0)161 275 5072
email Anna.Fildes-2@manchester.ac.uk
www.wtccmr.manchester.ac.uk

Manchester Wellcome Trust Clinical Research Facility (WTCRF)

Mission Statement: To provide a supportive, participant focused environment to host quality research of the highest scientific excellence from trial design to completion.

The Manchester Wellcome Trust Clinical Research Facility (WTCRF) has been operating since 2001 and provides a comprehensive dedicated research space and time to investigators from our five founding partners:

- The University of Manchester
- Central Manchester University Hospitals NHS Foundation Trust
- University Hospitals of South Manchester NHS Foundation Trust
- Salford Royal Hospitals NHS Foundation Trust
- Manchester Mental Health and Social Care NHS Trust

The WTCRF employs over 35 staff, including 17 clinical research nurses (3 paediatric nurses), support workers, a clinician and Technicians as well Laboratory Technicians and radiographers via service level agreements. The team supports a complement of over 100 active studies at any one time. Research areas supported include: Cancer; Cardiovascular; Congenital Disorders; Ear; Infection; Inflammatory and Immune System; Injuries and Accidents; Medicines for Children; Mental Health; Metabolic and Endocrine; Musculoskeletal; Neurological; Oral and Gastrointestinal; Renal and Urogenital; Reproductive Health and Childbirth; Respiratory; Skin and; Stroke

Study Types Supported include: Experimental medicine; Phase I; First-in-man; Pharmacokinetic studies; Pharmacodynamic studies; Phase II, III and IV; Epidemiological studies; Observational studies and; Screening studies

Facilities / Skills within the Facility include:

- 10 Inpatient beds
- 8 Consulting rooms (2 paediatric rooms)
- 4 Investigation rooms

Within these, services include phlebotomy, pulse-oximetry, ECG, pulse wave analysis and infusion devices.

Procedures carried out encompass minor surgery, bone biopsy, skin biopsy, glucose tolerance tests, food allergy testing, gluteal biopsy, cardiovascular challenges. The WTCRF's general laboratory facilities include centrifuge, fridges (4oC) for short term storage, freezers (-20oC) for short term storage + (-80oC), incubator, pH meter and fume cabinet.

Specialist (Human Performance) Facilities include gait analysis, isokinetic testing, isometric testing, spinal strength measurement, electromyography, whole body balance assessment, lumbar motion monitor, spirometry,

plethysmography, body composition analysis, lung function analysis and endothelial function.

The WTCRF offers the following imaging facilities: DXA Scanner; 1.5T MRI scanner; Ultrasound (Cardiac, Vascular, Obstetrics/Gynaecology); Optical Coherence Tomography and; Dark Field Sub-lingual Imaging

Contact

Professor Tony Heagerty, Medical Director or Mrs Helen Pidd, Operational Director
Wellcome Trust Clinical Research Facility
Manchester Royal Infirmary
Grafton Street
Manchester
M13 9WL

tel +44(0)161 906 7500
email information@wtcrf.nhs.uk
www.mhs.manchester.ac.uk/wtcrf

The Wolfson Molecular Imaging Centre (WMIC)

The Wolfson Molecular Imaging Centre (WMIC), as part of the University of Manchester, is an established clinical research-led, experimental medicine facility on the Christie Hospital site in South Manchester. Its primary focus is on Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) based research (mainly in the fields of oncology and neuroscience); along with the development of underlying methodologies to provide a means to undertake quantitative 'proof of concept' studies with unrivalled sensitivity and specificity.

The Centre is housed in a purpose designed building, and is equipped with state-of-the-art cyclotron and radiochemistry facilities, including a current Good Manufacturing Practice (cGMP) hot cell laboratory for aseptic tracer synthesis; the most advanced brain and body PET scanners with supporting chemical analysis laboratories; and a whole floor has been dedicated to molecular/biological laboratories including a small high resolution PET camera, in order to develop and characterise new PET tracers prior to their application in patients. The facility also houses a 1.5T MRI scanner, offering a broad range of advanced MR techniques, including: For example Magnetic Resonance Spectroscopy (MRS); Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion and Perfusion MRI.

The Centre is part of the broader Imaging facilities within the school of Cancer and Imaging Sciences, incorporating a broad range of imaging modalities across the University of Manchester campus. The school aims to establish one of the most advanced clinical and preclinical imaging research facilities internationally, providing a world-class environment in which investigators from both academia

and industry can enjoy productive and fruitful collaboration.

Contact

The University of Manchester,
Wolfson Molecular Imaging Centre
27 Palatine Road
Withington
Manchester
M20 3LJ

tel +44(0)161 275 0000
fax +44(0)161 275 0003
email WMICenquiries@manchester.ac.uk
www.manchester.ac.uk/wmic

MAHSC Partner Assets
and Linked Organisations Logos



Dr Linda Magee
Chief Operating Officer
MAHSC
Simon Building, Brunswick Street
Manchester M13 9PL

tel + 44 (0)161 306 0639
email mahsc@manchester.ac.uk
www.mahsc.ac.uk

